Infertility with obesity, PCOS, and prediabetes: choosing first-line ovulation induction
A 31-year-old nulliparous woman presents with 18 months of primary infertility. Menarche was at 13 years, and cycles occur every 45–90 days. BMI is 36 kg/m², waist circumference 104 cm, and she has acne and hirsutism. Pelvic ultrasound shows 14 follicles in each ovary and no dominant follicle; AMH is 9.8 ng/mL. Her partner's semen analysis is normal (concentration 48 million/mL, progressive motility 52%, morphology 6%). TSH is 2.1 mIU/L, prolactin is normal, HbA1c is 5.9%, fasting glucose is 101 mg/dL, and BP is 128/82 mmHg. She is keen to conceive and asks whether she should start clomiphene or “the drug that works better”.
1. Select first-line ovulation induction for this patient and justify it, including baseline assessment and monitoring.
Read the worked answer
She has WHO group II anovulation due to polycystic ovary syndrome, with Rotterdam criteria met by oligo-ovulation, clinical hyperandrogenism, and polycystic ovarian morphology. Letrozole is the preferred first-line oral agent. It is an aromatase inhibitor that reduces oestrogen feedback and increases FSH without the anti-oestrogenic endometrial and cervical effects of clomiphene. Randomised evidence shows higher live-birth rates with letrozole than clomiphene in PCOS, with fewer multiple pregnancies. Start letrozole 2.5 mg daily for five days, usually from day 2–5 of a spontaneous or induced bleed, and increase to 5 mg in later cycles if ovulation does not occur. Before treatment, confirm she is not pregnant, review TSH and prolactin, and check endometrial thickness and ovarian morphology. Counsel her that ultrasound monitoring is not mandatory for every cycle but is useful in the first cycle to confirm follicular response and exclude multiple follicles. Track ovulation with mid-luteal progesterone or ultrasound. Advise timed intercourse every 1–2 days around the expected ovulation. Because her BMI is 36 kg/m², combine treatment with structured weight management, as even 5–10% weight loss can restore ovulation and improve pregnancy outcomes.
2. What metabolic and preconception issues should be addressed before and during treatment?
Read the worked answer
Her HbA1c of 5.9% and fasting glucose of 101 mg/dL indicate prediabetes, and her BMI and waist circumference indicate central obesity. These increase the risks of gestational diabetes, hypertensive disorders, fetal macrosomia, and congenital anomalies, although the risk is lower than with established diabetes. Arrange lifestyle intervention with dietitian support and an exercise plan, aiming for gradual weight loss rather than a crash diet. Metformin 500–2000 mg daily can be considered for prediabetes and may improve ovulation and metabolic parameters, but it is not first-line for ovulation induction when letrozole is available. If metformin is started, continue it into early pregnancy if tolerated, with local guidance. Prescribe folic acid 5 mg daily because of obesity and prediabetes, starting at least one month before conception. Review BP; 128/82 mmHg is acceptable but should be monitored, and avoid ACE inhibitors or angiotensin receptor blockers if antihypertensives become necessary. Screen for obstructive sleep apnoea if she snores or has daytime somnolence. Arrange early gestational diabetes screening if she conceives, and counsel her about the increased risk of pre-eclampsia and thromboembolism. Document the plan in a preconception counselling letter.
3. She ovulates on letrozole 5 mg but has not conceived after four cycles. Outline your next steps and counsel her about multiple pregnancy and ovarian hyperstimulation risk.
Read the worked answer
After four ovulatory cycles with letrozole and normal semen analysis, she has not conceived, so reassess before escalating. Confirm ovulation with progesterone or ultrasound, check that intercourse timing is correct, and review her weight and metabolic control. Reassess the tubal factor with hysterosalpingography if not already done, and confirm that the uterine cavity is normal. Options include continuing letrozole for up to six cycles, adding intrauterine insemination, or referring for gonadotropin ovulation induction or IVF. Adding metformin may be reasonable if she has prediabetes, but it is not a substitute for ovulation induction. If gonadotropins are used, the risk of multiple pregnancy and ovarian hyperstimulation syndrome rises substantially; use low-dose step-up protocols with ultrasound monitoring and cancel or convert cycles if more than two dominant follicles develop. Letrozole carries a lower multiple pregnancy rate than clomiphene or gonadotropins, but twins still occur. Counsel her that obesity reduces the chance of success and increases pregnancy risk, and that IVF may be more efficient if tubal or male factors emerge. Discuss the emotional and financial burden, and offer a clear timeline rather than repeated ineffective cycles.